Logo image of SVRA

SAVARA INC (SVRA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SVRA - US8051111016 - Common Stock

6.4 USD
-0.04 (-0.62%)
Last: 12/24/2025, 3:59:32 PM
6.4 USD
0 (0%)
After Hours: 12/24/2025, 3:59:32 PM
Fundamental Rating

2

Taking everything into account, SVRA scores 2 out of 10 in our fundamental rating. SVRA was compared to 530 industry peers in the Biotechnology industry. SVRA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SVRA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SVRA had negative earnings in the past year.
SVRA had a negative operating cash flow in the past year.
In the past 5 years SVRA always reported negative net income.
SVRA had a negative operating cash flow in each of the past 5 years.
SVRA Yearly Net Income VS EBIT VS OCF VS FCFSVRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -82.03%, SVRA is not doing good in the industry: 69.06% of the companies in the same industry are doing better.
The Return On Equity of SVRA (-122.48%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -82.03%
ROE -122.48%
ROIC N/A
ROA(3y)-34.4%
ROA(5y)-35.67%
ROE(3y)-43.45%
ROE(5y)-47.43%
ROIC(3y)N/A
ROIC(5y)N/A
SVRA Yearly ROA, ROE, ROICSVRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SVRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SVRA Yearly Profit, Operating, Gross MarginsSVRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for SVRA has been increased compared to 1 year ago.
The number of shares outstanding for SVRA has been increased compared to 5 years ago.
SVRA has a better debt/assets ratio than last year.
SVRA Yearly Shares OutstandingSVRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
SVRA Yearly Total Debt VS Total AssetsSVRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 9.29 indicates that SVRA is not in any danger for bankruptcy at the moment.
SVRA has a Altman-Z score of 9.29. This is amongst the best in the industry. SVRA outperforms 81.32% of its industry peers.
A Debt/Equity ratio of 0.32 indicates that SVRA is not too dependend on debt financing.
SVRA has a worse Debt to Equity ratio (0.32) than 70.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Altman-Z 9.29
ROIC/WACCN/A
WACCN/A
SVRA Yearly LT Debt VS Equity VS FCFSVRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 7.65 indicates that SVRA has no problem at all paying its short term obligations.
SVRA has a better Current ratio (7.65) than 73.02% of its industry peers.
SVRA has a Quick Ratio of 7.65. This indicates that SVRA is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of SVRA (7.65) is better than 73.02% of its industry peers.
Industry RankSector Rank
Current Ratio 7.65
Quick Ratio 7.65
SVRA Yearly Current Assets VS Current LiabilitesSVRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

SVRA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -23.26%.
EPS 1Y (TTM)-23.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SVRA will show a very strong growth in Earnings Per Share. The EPS will grow by 25.91% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-12.15%
EPS Next 2Y5.22%
EPS Next 3Y10.67%
EPS Next 5Y25.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SVRA Yearly Revenue VS EstimatesSVRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2018 2020 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
SVRA Yearly EPS VS EstimatesSVRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SVRA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SVRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SVRA Price Earnings VS Forward Price EarningsSVRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SVRA Per share dataSVRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.22%
EPS Next 3Y10.67%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SVRA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SAVARA INC

NASDAQ:SVRA (12/24/2025, 3:59:32 PM)

After market: 6.4 0 (0%)

6.4

-0.04 (-0.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners78.39%
Inst Owner Change-4.97%
Ins Owners2.37%
Ins Owner Change-1.2%
Market Cap1.30B
Revenue(TTM)N/A
Net Income(TTM)-115.60M
Analysts85.71
Price Target10.52 (64.37%)
Short Float %8.1%
Short Ratio6.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.07%
Min EPS beat(2)-12.66%
Max EPS beat(2)-3.49%
EPS beat(4)1
Avg EPS beat(4)-5.53%
Min EPS beat(4)-14.48%
Max EPS beat(4)8.5%
EPS beat(8)3
Avg EPS beat(8)-3.35%
EPS beat(12)6
Avg EPS beat(12)-3.68%
EPS beat(16)8
Avg EPS beat(16)-0.68%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)5.38%
EPS NQ rev (1m)1.99%
EPS NQ rev (3m)5.72%
EPS NY rev (1m)0.65%
EPS NY rev (3m)-0.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 13.8
P/tB 15.74
EV/EBITDA N/A
EPS(TTM)-0.53
EYN/A
EPS(NY)-0.42
Fwd EYN/A
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0
BVpS0.46
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -82.03%
ROE -122.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.4%
ROA(5y)-35.67%
ROE(3y)-43.45%
ROE(5y)-47.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.63%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.65
Quick Ratio 7.65
Altman-Z 9.29
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)145.23%
Cap/Depr(5y)348.79%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-23.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.27%
EPS Next Y-12.15%
EPS Next 2Y5.22%
EPS Next 3Y10.67%
EPS Next 5Y25.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-36.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.72%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-123.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-124.39%
OCF growth 3YN/A
OCF growth 5YN/A

SAVARA INC / SVRA FAQ

Can you provide the ChartMill fundamental rating for SAVARA INC?

ChartMill assigns a fundamental rating of 2 / 10 to SVRA.


Can you provide the valuation status for SAVARA INC?

ChartMill assigns a valuation rating of 0 / 10 to SAVARA INC (SVRA). This can be considered as Overvalued.


What is the profitability of SVRA stock?

SAVARA INC (SVRA) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for SVRA stock?

The Earnings per Share (EPS) of SAVARA INC (SVRA) is expected to decline by -12.15% in the next year.